13 December 2018 - Report will be subject of New England CEPAC meeting in July 2019; Open Input now being accepted until 8 January 2019.

The ICER announced today that it plans to assess the comparative clinical effectiveness and value of treatments for Duchenne muscular dystrophy. The report will be reviewed during a public meeting of the New England Comparative Effectiveness Public Advisory Council (New England CEPAC) in July of 2019.

ICER's assessment will focus on eteplirsen (Exondys 51, Sarepta Therapeutics) and golodirsen (Sarepta Therapeutics). Eteplirsen was approved by the FDA in September of 2016, and golodirsen has an anticipated FDA approval decision expected in the middle of 2019.

Read ICER announcement